Skip to main content
main-content
Erschienen in: Die Pathologie 2/2019

07.03.2019 | Pathologie | CME

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

verfasst von: Prof. Dr. A. Lebeau, C. Denkert, P. Sinn, M. Schmidt, A. Wöckel

Erschienen in: Die Pathologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Es werden die für Pathologen relevanten inhaltlichen Änderungen der aktualisierten interdisziplinären S3-Leitlinie „Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms“ dargestellt und im Kontext der neuesten Evidenz erörtert. Hierzu zählen die Empfehlungen zur Risikoabschätzung mittels Ki-67 sowie zum Einsatz von Multigentests bei der Entscheidung für oder gegen eine adjuvante Chemotherapie beim Östrogenrezeptor(ER)-/Progesteronrezeptor(PR)-positiven und „human-epidermal-growth-factor-receptor“(HER)-2-negativen invasiven Mammakarzinom. Außerdem wird die Bewertung des HER2-Status erläutert. Zusätzlich wird dargelegt, welcher Sicherheitsabstand oder Resektionsrandstatus für die Resektion eines duktalen Carcinoma in situ (DCIS) und invasiven Mammakarzinoms als ausreichend erachtet wird und welche klinischen Konsequenzen aus dem Nachweis einer Risikoläsion in einer Stanz- bzw. Vakuumbiopsie oder am Resektionsrand eines Mammaresektats gezogen werden sollten.
Literatur
2.
Zurück zum Zitat Houssami N, Macaskill P, Marinovich ML et al (2014) The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 21:717–730 CrossRef Houssami N, Macaskill P, Marinovich ML et al (2014) The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 21:717–730 CrossRef
3.
Zurück zum Zitat Moran MS, Schnitt SJ, Giuliano AE et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507–1515 CrossRef Moran MS, Schnitt SJ, Giuliano AE et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507–1515 CrossRef
4.
Zurück zum Zitat Buchholz TA, Somerfield MR, Griggs JJ et al (2014) Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 32:1502–1506 CrossRef Buchholz TA, Somerfield MR, Griggs JJ et al (2014) Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 32:1502–1506 CrossRef
5.
Zurück zum Zitat Sinn HP, Anton HW, Magener A et al (1998) Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34:646–653 CrossRef Sinn HP, Anton HW, Magener A et al (1998) Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34:646–653 CrossRef
6.
Zurück zum Zitat Marinovich ML, Azizi L, Macaskill P et al (2016) The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 23:3811–3821 CrossRef Marinovich ML, Azizi L, Macaskill P et al (2016) The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 23:3811–3821 CrossRef
7.
Zurück zum Zitat Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-conserving surgery with whole-breast irradiation in ductal carcinoma In Situ. J Clin Oncol 34:4040–4046 CrossRef Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-conserving surgery with whole-breast irradiation in ductal carcinoma In Situ. J Clin Oncol 34:4040–4046 CrossRef
9.
Zurück zum Zitat Fitzsullivan E, Lari SA, Smith B et al (2013) Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol 20:4103–4112 CrossRef Fitzsullivan E, Lari SA, Smith B et al (2013) Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol 20:4103–4112 CrossRef
10.
Zurück zum Zitat Amendoeira I, Apostolikas N, Bellocq JP et al (2006) Quality assurance guidelines for pathology: Cytological and histological non-operative procedures. In: Perry N, Broeders M, de Wolf C, Störnberg S, Holland R, von Karsa L (Hrsg) European guidelines for quality assurance in breast cancer screening and diagnosis. European Communities, Luxemburg, S 221–256 Amendoeira I, Apostolikas N, Bellocq JP et al (2006) Quality assurance guidelines for pathology: Cytological and histological non-operative procedures. In: Perry N, Broeders M, de Wolf C, Störnberg S, Holland R, von Karsa L (Hrsg) European guidelines for quality assurance in breast cancer screening and diagnosis. European Communities, Luxemburg, S 221–256
11.
Zurück zum Zitat Lee AH, Anderson N, Carder P et al (2016) Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. G 150. The Royal College of Pathologists, London Lee AH, Anderson N, Carder P et al (2016) Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. G 150. The Royal College of Pathologists, London
12.
Zurück zum Zitat Wittekind C (2017) TNM-Klassifikation maligner Tumoren. Wiley-VCH, Weinheim Wittekind C (2017) TNM-Klassifikation maligner Tumoren. Wiley-VCH, Weinheim
13.
Zurück zum Zitat Lakhani SR, Ellis I, Schnitt S et al (2012) WHO classification of tumours of the breast. IARC Press, Lyon Lakhani SR, Ellis I, Schnitt S et al (2012) WHO classification of tumours of the breast. IARC Press, Lyon
14.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410 CrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410 CrossRef
15.
Zurück zum Zitat Ellis IO, Al-Sam S, Anderson N et al (2016) Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. G 148 LR. The Royal College of Pathologists, London Ellis IO, Al-Sam S, Anderson N et al (2016) Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. G 148 LR. The Royal College of Pathologists, London
16.
Zurück zum Zitat IQWiG (2014) Bestimmung der Antigenexpressionslevel von uPA und PAI-1 beim primären Mammakarzinom mit intermediärem Rückfallrisiko nach R0-Primäroperation. D13-02. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln IQWiG (2014) Bestimmung der Antigenexpressionslevel von uPA und PAI-1 beim primären Mammakarzinom mit intermediärem Rückfallrisiko nach R0-Primäroperation. D13-02. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln
17.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795 CrossRef Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795 CrossRef
18.
Zurück zum Zitat Nofech-Mozes S, Vella ET, Dhesy-Thind S et al (2012) Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. Clin Oncol 24:684–696 CrossRef Nofech-Mozes S, Vella ET, Dhesy-Thind S et al (2012) Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. Clin Oncol 24:684–696 CrossRef
19.
Zurück zum Zitat Curigliano G, Burstein HJ, Winer PE et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700–1712 CrossRef Curigliano G, Burstein HJ, Winer PE et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700–1712 CrossRef
20.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG et al (2015) Reply to E.A. Rakha et al. J Clin Oncol 33:1302–1304 CrossRef Wolff AC, Hammond ME, Hicks DG et al (2015) Reply to E.A. Rakha et al. J Clin Oncol 33:1302–1304 CrossRef
21.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013 CrossRef Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013 CrossRef
22.
Zurück zum Zitat Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122 CrossRef Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122 CrossRef
23.
Zurück zum Zitat Rakha EA, Pigera M, Shaaban A et al (2015) National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. J Clin Oncol 33:1301–1302 CrossRef Rakha EA, Pigera M, Shaaban A et al (2015) National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. J Clin Oncol 33:1301–1302 CrossRef
24.
Zurück zum Zitat Rakha EA, Starczynski J, Lee AH et al (2014) The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology 64:609–615 CrossRef Rakha EA, Starczynski J, Lee AH et al (2014) The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology 64:609–615 CrossRef
25.
Zurück zum Zitat Petrelli F, Viale G, Cabiddu M et al (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 153:477–491 CrossRef Petrelli F, Viale G, Cabiddu M et al (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 153:477–491 CrossRef
26.
Zurück zum Zitat Sonnenblick A, Francis PA, Azim HA Jr. et al (2015) Final 10-year results of the Breast International Group 2‑98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer 51:1481–1489 CrossRef Sonnenblick A, Francis PA, Azim HA Jr. et al (2015) Final 10-year results of the Breast International Group 2‑98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer 51:1481–1489 CrossRef
27.
Zurück zum Zitat Gluz O, Nitz UA, Christgen M et al (2016) West German Study Group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34:2341–2349 CrossRef Gluz O, Nitz UA, Christgen M et al (2016) West German Study Group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34:2341–2349 CrossRef
28.
Zurück zum Zitat Nitz U, Gluz O, Huober J et al (2014) Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 25:1551–1557 CrossRef Nitz U, Gluz O, Huober J et al (2014) Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 25:1551–1557 CrossRef
29.
Zurück zum Zitat Harris LN, Ismaila N, Mcshane LM et al (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134–1150 CrossRef Harris LN, Ismaila N, Mcshane LM et al (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134–1150 CrossRef
30.
Zurück zum Zitat Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552 CrossRef Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552 CrossRef
31.
Zurück zum Zitat Leung SCY, Nielsen TO, Zabaglo L et al (2016) Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2:16014 CrossRef Leung SCY, Nielsen TO, Zabaglo L et al (2016) Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2:16014 CrossRef
32.
Zurück zum Zitat Polley MY, Leung SC, Mcshane LM et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897–1906 CrossRef Polley MY, Leung SC, Mcshane LM et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897–1906 CrossRef
33.
Zurück zum Zitat Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664 CrossRef Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664 CrossRef
34.
Zurück zum Zitat Christgen M, Winkens W, Kreipe HH (2014) Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67. Pathologe 35:54–60 CrossRef Christgen M, Winkens W, Kreipe HH (2014) Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67. Pathologe 35:54–60 CrossRef
35.
Zurück zum Zitat Varga Z, Cassoly E, Li Q et al (2015) Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS ONE 10:e123435 CrossRef Varga Z, Cassoly E, Li Q et al (2015) Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS ONE 10:e123435 CrossRef
37.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784 CrossRef Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784 CrossRef
38.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717 CrossRef Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717 CrossRef
39.
Zurück zum Zitat Iqwig (2016) Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom. Abschlussbericht. Version 1.0. D14-01. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln Iqwig (2016) Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom. Abschlussbericht. Version 1.0. D14-01. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln
40.
Zurück zum Zitat Gnant M, Sestak I, Filipits M et al (2015) Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol 26:1685–1691 CrossRef Gnant M, Sestak I, Filipits M et al (2015) Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol 26:1685–1691 CrossRef
41.
Zurück zum Zitat Wolmark N, Mamounas EP, Baehner FL et al (2016) Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of Tamoxifen: results from NRG oncology/national surgical adjuvant breast and bowel project B‑28 and B‑14. J Clin Oncol 34:2350–2358 CrossRef Wolmark N, Mamounas EP, Baehner FL et al (2016) Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of Tamoxifen: results from NRG oncology/national surgical adjuvant breast and bowel project B‑28 and B‑14. J Clin Oncol 34:2350–2358 CrossRef
42.
Zurück zum Zitat Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121 CrossRef Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121 CrossRef
43.
Zurück zum Zitat Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014 CrossRef Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014 CrossRef
44.
Zurück zum Zitat Cardoso F, Van’t Veer LJ, Bogaerts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729 CrossRef Cardoso F, Van’t Veer LJ, Bogaerts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729 CrossRef
45.
Zurück zum Zitat Krop I, Ismaila N, Andre F et al (2017) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 35:2838–2847 CrossRef Krop I, Ismaila N, Andre F et al (2017) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 35:2838–2847 CrossRef
47.
Zurück zum Zitat Stein RC, Dunn JA, Bartlett JM et al (2016) OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol Assess 20:xxiii–xxix, 1–201 CrossRef Stein RC, Dunn JA, Bartlett JM et al (2016) OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol Assess 20:xxiii–xxix, 1–201 CrossRef
Metadaten
Titel
Update der S3-Leitlinie Mammakarzinom
Was gibt es Neues für Pathologen?
verfasst von
Prof. Dr. A. Lebeau
C. Denkert
P. Sinn
M. Schmidt
A. Wöckel
Publikationsdatum
07.03.2019
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 2/2019
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-019-0578-3

Weitere Artikel der Ausgabe 2/2019

Die Pathologie 2/2019 Zur Ausgabe

Mitteilungen der Deutschen Gesellschaft für Pathologie

Mitteilungen der Deutschen Gesellschaft für Pathologie

Passend zum Thema

DKK 2022

Dossier zum Deutschen Krebskongress

Im CityCube Berlin dreht sich vom 13. bis 16. November 2022 alles um die Krebsmedizin: „Schnittstellen zwischen Innovation und Versorgung“ lautet das Motto des 35. Deutschen Krebskongresses (DKK). Wir berichten tagesaktuell von der größten onkologischen Fachtagung in Deutschland. News, Interviews, Diskussionen und Veranstaltungshinweise sammelt unser Kongressdossier.

Eine Kooperation von Springer Medizin mit der Deutschen Krebsgesellschaft und der Deutschen Krebshilfe.

Mehr